DK3270965T3 - Cd48-antistoffer og konjugater deraf - Google Patents
Cd48-antistoffer og konjugater deraf Download PDFInfo
- Publication number
- DK3270965T3 DK3270965T3 DK16765773.3T DK16765773T DK3270965T3 DK 3270965 T3 DK3270965 T3 DK 3270965T3 DK 16765773 T DK16765773 T DK 16765773T DK 3270965 T3 DK3270965 T3 DK 3270965T3
- Authority
- DK
- Denmark
- Prior art keywords
- conjugates
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562134981P | 2015-03-18 | 2015-03-18 | |
PCT/US2016/022943 WO2016149535A1 (en) | 2015-03-18 | 2016-03-17 | Cd48 antibodies and conjugates thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3270965T3 true DK3270965T3 (da) | 2020-06-08 |
Family
ID=56919489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16765773.3T DK3270965T3 (da) | 2015-03-18 | 2016-03-17 | Cd48-antistoffer og konjugater deraf |
Country Status (17)
Country | Link |
---|---|
US (2) | US10722592B2 (da) |
EP (2) | EP3662933A1 (da) |
JP (2) | JP6892826B2 (da) |
KR (1) | KR20170128256A (da) |
CN (1) | CN107530422B (da) |
AU (1) | AU2016232839B2 (da) |
BR (1) | BR112017019617A2 (da) |
CA (1) | CA2976740A1 (da) |
DK (1) | DK3270965T3 (da) |
EA (2) | EA035374B1 (da) |
ES (1) | ES2795818T3 (da) |
HK (1) | HK1248538A1 (da) |
IL (1) | IL254027B (da) |
MX (1) | MX2017011432A (da) |
SG (1) | SG11201706786UA (da) |
WO (1) | WO2016149535A1 (da) |
ZA (1) | ZA201705935B (da) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017237186A1 (en) | 2016-03-25 | 2018-11-01 | Seagen Inc. | Process for the preparation of PEGylated drug-linkers and intermediates thereof |
US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
EP3802546A4 (en) | 2018-05-29 | 2021-12-29 | Intocell, Inc. | Novel benzodiazepine derivatives and uses thereof |
WO2020163225A1 (en) | 2019-02-05 | 2020-08-13 | Seattle Genetics, Inc. | Anti-cd228 antibodies and antibody-drug conjugates |
CN115151564A (zh) | 2019-10-04 | 2022-10-04 | 思进股份有限公司 | 抗pd-l1抗体和抗体-药物缀合物 |
WO2021067820A1 (en) | 2019-10-04 | 2021-04-08 | Seagen Inc. | Formulation of antibody-drug conjugate |
CN114929284A (zh) | 2019-10-04 | 2022-08-19 | 西根公司 | 喜树碱肽缀合物 |
IL297167A (en) | 2020-04-10 | 2022-12-01 | Seagen Inc | Charging variant connectors |
EP4251648A2 (en) * | 2020-11-24 | 2023-10-04 | Novartis AG | Anti-cd48 antibodies, antibody drug conjugates, and uses thereof |
JP2023553808A (ja) * | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | Mcl-1阻害剤抗体-薬物コンジュゲートおよび使用方法 |
CA3221398A1 (en) | 2021-05-28 | 2022-12-01 | Seagen Inc. | Anthracycline antibody conjugates |
WO2023178289A2 (en) | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
JP2000509015A (ja) * | 1996-03-27 | 2000-07-18 | シーアールシー フォー バイオファーマシューティカル リサーチ ピーティーワイ.リミテッド | T細胞及びb細胞リンパ腫及び白血病の治療のためのcd48に対する抗体の使用 |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
US20070178072A1 (en) | 2004-03-31 | 2007-08-02 | Kirin Beer Kabushiki Kaisha | Method for inducing differentiation of regulatory t cells usinggip-anchored protein agonist and pharmaceutical composition therefor ( as amended |
MXPA06011796A (es) * | 2004-04-16 | 2007-05-07 | Macrogenics Inc | Anticuerpos especificos de fc(riib y metodos para el uso de los mismos. |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
CA2614436C (en) | 2005-07-07 | 2016-05-17 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
AU2006269940C1 (en) * | 2005-07-18 | 2013-11-07 | Seagen Inc. | Beta-glucuronide-linker drug conjugates |
DK2913343T3 (da) * | 2005-12-20 | 2018-11-26 | Sbi Biotech Co Ltd | Anti-ILT7-antistof |
HUE031533T2 (hu) | 2007-10-19 | 2017-07-28 | Seattle Genetics Inc | CD19-kötõszerek valamint alkalmazásuk |
EP2220122A2 (en) * | 2007-11-13 | 2010-08-25 | Teva Biopharmaceuticals USA, Inc. | Humanized antibodies against tl1a |
WO2009099580A2 (en) | 2008-02-05 | 2009-08-13 | Monsanto Technology, Llc | Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits |
US9097717B2 (en) * | 2009-04-10 | 2015-08-04 | Osaka University | Methods of killing myeloma stem and precursor cells by administering anti-CD48 antibodies |
EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
AR083044A1 (es) * | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
WO2012140627A1 (en) * | 2011-04-15 | 2012-10-18 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
EP3296320A1 (en) * | 2012-03-08 | 2018-03-21 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
KR102433686B1 (ko) * | 2012-05-15 | 2022-08-19 | 씨젠 인크. | 자가-안정화 링커 접합체 |
US11103593B2 (en) | 2013-10-15 | 2021-08-31 | Seagen Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
-
2016
- 2016-03-17 EP EP19219476.9A patent/EP3662933A1/en not_active Withdrawn
- 2016-03-17 JP JP2017548953A patent/JP6892826B2/ja active Active
- 2016-03-17 AU AU2016232839A patent/AU2016232839B2/en not_active Ceased
- 2016-03-17 EA EA201792055A patent/EA035374B1/ru unknown
- 2016-03-17 BR BR112017019617-4A patent/BR112017019617A2/pt not_active IP Right Cessation
- 2016-03-17 EP EP16765773.3A patent/EP3270965B1/en active Active
- 2016-03-17 KR KR1020177024226A patent/KR20170128256A/ko not_active Application Discontinuation
- 2016-03-17 MX MX2017011432A patent/MX2017011432A/es unknown
- 2016-03-17 CA CA2976740A patent/CA2976740A1/en not_active Abandoned
- 2016-03-17 ES ES16765773T patent/ES2795818T3/es active Active
- 2016-03-17 SG SG11201706786UA patent/SG11201706786UA/en unknown
- 2016-03-17 CN CN201680013161.1A patent/CN107530422B/zh active Active
- 2016-03-17 WO PCT/US2016/022943 patent/WO2016149535A1/en active Application Filing
- 2016-03-17 US US15/557,910 patent/US10722592B2/en active Active
- 2016-03-17 EA EA201992756A patent/EA201992756A3/ru unknown
- 2016-03-17 DK DK16765773.3T patent/DK3270965T3/da active
-
2017
- 2017-08-16 IL IL254027A patent/IL254027B/en active IP Right Grant
- 2017-08-31 ZA ZA2017/05935A patent/ZA201705935B/en unknown
-
2018
- 2018-06-26 HK HK18108175.0A patent/HK1248538A1/zh unknown
-
2020
- 2020-05-26 JP JP2020091335A patent/JP2020141700A/ja active Pending
- 2020-06-04 US US16/892,529 patent/US20200289661A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112017019617A2 (pt) | 2018-05-22 |
KR20170128256A (ko) | 2017-11-22 |
US20180092984A1 (en) | 2018-04-05 |
IL254027B (en) | 2021-05-31 |
ES2795818T3 (es) | 2020-11-24 |
CN107530422B (zh) | 2021-09-21 |
EA201992756A3 (ru) | 2020-06-30 |
SG11201706786UA (en) | 2017-09-28 |
US10722592B2 (en) | 2020-07-28 |
EP3270965B1 (en) | 2020-05-06 |
JP6892826B2 (ja) | 2021-06-23 |
US20200289661A1 (en) | 2020-09-17 |
EA201792055A1 (ru) | 2018-01-31 |
MX2017011432A (es) | 2017-11-10 |
EP3270965A1 (en) | 2018-01-24 |
EP3662933A1 (en) | 2020-06-10 |
EA035374B1 (ru) | 2020-06-03 |
JP2020141700A (ja) | 2020-09-10 |
AU2016232839B2 (en) | 2021-02-25 |
ZA201705935B (en) | 2021-01-27 |
HK1248538A1 (zh) | 2018-10-19 |
IL254027A0 (en) | 2017-10-31 |
EP3270965A4 (en) | 2018-09-05 |
CN107530422A (zh) | 2018-01-02 |
CA2976740A1 (en) | 2016-09-22 |
AU2016232839A1 (en) | 2017-08-31 |
JP2018509908A (ja) | 2018-04-12 |
EA201992756A2 (ru) | 2020-03-31 |
WO2016149535A1 (en) | 2016-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3458479T3 (da) | Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater | |
IL288391A (en) | Anti-cd123 antibodies and conjugates and their history | |
IL290457A (en) | Antibodies and their conjugates | |
DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
DK3515487T3 (da) | Bispecifikke anti-MUC16-CD3-antistoffer og anti-MUC16-lægemiddelkonjugater | |
DK3592393T3 (da) | Frigørbare konjugater | |
DK3307274T3 (da) | Anti-cd123-antistoffer og konjugater deraf | |
DK3443009T3 (da) | Anti-tim-3-antistoffer og sammensætninger | |
KR102162129B9 (ko) | 항-갈렉틴-9 항체 및 이의 용도 | |
DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
DK3579883T3 (da) | Pyrrolobenzodiazepin-antistofkonjugater | |
DK3350220T3 (da) | Anti-pro/latente-myostatin-antistoffer og anvendelser deraf | |
BR112016021717A2 (pt) | anticorpos anti-egfr e conjugados anticorpo-fármaco | |
DK3191135T3 (da) | Anti-HER2-antistoffer og immunokonjugater | |
DK3229838T3 (da) | Anti-C10orf54-antistoffer og anvendelser deraf | |
DK3270965T3 (da) | Cd48-antistoffer og konjugater deraf | |
DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
DK3258951T3 (da) | Anti-pvrig antistoffer og fremgangsmåder for anvendelse | |
DK3463435T3 (da) | Alpha-synuklein-antistoffer og anvendelser deraf | |
DK3316909T3 (da) | Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder | |
DK3102244T3 (da) | Antistoflægemiddelkonjugater og immuntoksiner | |
DK3532499T3 (da) | ANTI-IL-33-antistoffer og anvendelser deraf | |
DK3113797T3 (da) | Antistoffer, anvendelser og fremgangsmåder | |
DK3334500T3 (da) | Multiligand-lægemiddelskonjugater og anvendelser deraf | |
DK3402821T3 (da) | Psma-bindende antistof og anvendelser deraf |